The efficacy of infliximab for treating ulcerative colitis (UC) and indeterminate colitis has been poorly assessed. Preliminary results are conflicting.
In this study, doctors from Europe reviewed the records of 30 patients treated with infliximab for ulcerative colitis (n = 19) or indeterminate colitis (n = 11).
They found that infliximab was given because of steroid resistance in 18 patients, dependence in 5 or intolerance in 7. A further 5 patients had failed on cyclosporine, and 19 patients had a severe flare-up.
Median duration of follow-up was 10 months.
|The probability of colectomy was 33% at month 12.|
|Alimentary Pharmacology and Therapeutics|
The team determined that in the 28 patients with active disease, the response rate was 75% at day 7. They found that 43% had a complete remission at day 7 and 50% at month 1.
However, among the 22 responders, the probability of relapse was 73% at month 6.
The investigators found that the probability of complete remission without steroids was 57% at month 6.
However, the probability of colectomy was 33% at month 12.
Furthermore, in indeterminate colitis the response rate was only 50% at day 7 and 30% at month 1.
Concomitant use of antimetabolite agents was associated with better results.
Dr Gornet's team concluded, "Infliximab was able to induce a rapid response in some patients with UC or indeterminate colitis refractory to conventional treatment".
"Long-term results were less favourable, with frequent relapses, and about one-third of the patients required a colectomy".